Lipolysis gene expression

The term "lipolysis gene expression" refers broadly to the transcriptional regulation of genes involved in lipolysis, the process of hydrolyzing triglycerides into free fatty acids and glycerol[1][3]. Lipolysis itself does not name a single molecule or receptor, but rather a biological process involving multiple enzymes (e.g., adipose triglyceride lipase, ATGL, and hormone-sensitive lipase, HSL), regulatory proteins, and transcription factors[1][3]. The transcriptional control of lipolytic genes is complex and involves several transcription factors, including PPARα, PPARγ, SREBP-1, IRF2BP2, and others[1][2][3]. These factors regulate lipolysis by modulating the expression of lipolytic enzymes and related metabolic genes, often in response to metabolic signals such as β-adrenergic stimuli[1][3]. Lipolysis gene expression is not a therapeutic target per se—rather, specific molecules involved in this process (e.g., ATGL, HSL, ABHD5, G0S2, PNPLA3, PPARs, SREBP-1, IRF2BP2) are potential targets for modulating lipid metabolism and treating diseases such as obesity and metabolic syndrome[3][4]. The term is too broad and non-specific to serve as a discrete target; it describes a process rather than a single entity. Therefore, it is not correct to use "lipolysis gene expression" as a target name in drug discovery or molecular biology databases. A more precise approach would be to identify the individual transcription factors, enzymes, or regulatory proteins involved in the transcriptional control of lipolysis.